Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
- DOI
- 10.1016/s2468-1253(21)00295-8
- Published
- 2022 Jan
- Container
- The lancet. Gastroenterology & hepatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s2468-1253-21-00295-8,
title = {Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.},
author = {Vermeire S and Lakatos PL and Ritter T and Hanauer S and Bressler B and Khanna R and Isaacs K and Shah S and Kadva A and Tyrrell H and Oh YS and Tole S and Chai A and Pulley J and Eden C and Zhang W and Feagan BG and LAUREL Study Group},
year = {2022},
journal = {The lancet. Gastroenterology \& hepatology},
doi = {10.1016/s2468-1253(21)00295-8},
url = {https://doi.org/10.1016/s2468-1253(21)00295-8}
}RIS
TY - JOUR TI - Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. AU - Vermeire S AU - Lakatos PL AU - Ritter T AU - Hanauer S AU - Bressler B AU - Khanna R AU - Isaacs K AU - Shah S AU - Kadva A AU - Tyrrell H AU - Oh YS AU - Tole S AU - Chai A AU - Pulley J AU - Eden C AU - Zhang W AU - Feagan BG AU - LAUREL Study Group PY - 2022 JO - The lancet. Gastroenterology & hepatology DO - 10.1016/s2468-1253(21)00295-8 UR - https://doi.org/10.1016/s2468-1253(21)00295-8 ER -
APA
S, V., PL, L., T, R., S, H., B, B., R, K., K, I., S, S., A, K., H, T., YS, O., S, T., A, C., J, P., C, E., W, Z., BG, F., & Group, L. S. (2022). Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.. The lancet. Gastroenterology & hepatology. https://doi.org/10.1016/s2468-1253(21)00295-8
Source records
- pubmed · retrieved 2026-09-26T06:08:41.465Z